Karuna Therapeutics (KRTX) has filed to raise gross proceeds of up to $70 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing new therapeutics for debilitating neuropsychiatric conditions with high unmet medical needs.
KRTX has a late 2019 potential catalyst milestone from its Phase 2 trials and reasonable IPO valuation expectations, so the IPO presents a potential investment opportunity for life science investors with a hold timeframe of at least one year.
Company & Technology
Boston, Massachusetts-based Karuna was founded in 2009 to identify and develop